Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > How Barclays Capital values Small Cap Oncology names

<< Previous

Bullboard Posts

Next >>

Comment by ANALIAS00on Feb 04, 2021 9:35am

91 Views

Post# 32469040

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How Barclays Capital values Small Cap Oncology names

Me to. Is the a way TH could be challenged about their decision to get financed that way if they were so confident about their short term future ? I dont get it. I should be happy and I find a way to feel we got rubbed.